RD24065From cardiovascular protection to cardiovascular risk: the metamorphosis of menopausal hormone therapy
The metamorphosis from perceived cardiovascular protection to perceived cardiovascular risk, a perception largely led by the Women’s Health Initiative study, has shifted the clinician’s risk/benefit decision-making away from prescribing menopausal hormone therapy (MHT) for menopausal symptoms. A more nuanced view of the literature and the greater availability of different modes of delivery and formulations of MHT should give the clinician the knowledge and confidence to prescribe appropriate MHT for the greater benefit of midlife health and cardiovascular safety. Image by Bronwyn G. A. Stuckey.
RD24065 Abstract | RD24065 Full Text | RD24065PDF (263 KB) Open Access Article